Isabelle Quéré is a vascular medicine physician and Professor of Vascular Medicine at Montpellier University, Montpellier, France. She is a founding member of the French Society of Vascular Medicine (SFMV), a member of the executive boards of the ILF and ESVM, and a member of the ISL, ICC, and ISSVA society and groups. Her medical background is in internal medicine prior to her qualification in vascular medicine. She has been running the Vascular Medicine Department of the Montpellier University Hospital since 2003 and the national Lymphoedema framework “Partenariat Français du Lymphoedème” in France since 2012.
The Vascular Medicine Department of the Montpellier University Hospital is a national referral centre for rare lymphatic and vascular anomalies within the FAVA-Multi network and a LERN Comprehensive Centre for Primary Lymphoedema. Active areas of research are conducted in collaboration with colleagues from 12 countries under the umbrella of the ILF for the LIMPRINT Program and psychosocial research for children with Lymphoedema. Characterization of the natural history of the various genetic lymphatic anomalies and the development of new personalized therapeutic approaches are conducted in collaboration with the Lymphoedema Research Group in the laboratory of Pr Miikka Vikkula and the laboratory of Pr Laurence Boon at the Centre for Vascular and Lymphatic Anomalies, both located at the Université Catholique de Louvain.
- Burian EA, Karlsmark T, Franks PJ, Keeley V, Quéré I, Moffatt CJ. Cellulitis in chronic oedema of the lower leg: an international cross-sectional study. Br J Dermatol. 2021 Jan 6. doi: 10.1111/bjd.19803.
- Quéré I, Stasi E, Mestre S, Roessler J, Roccatello D, Moffatt C. International Camps for Children with Lymphoedema and Lymphatic anomalies. When education links with Psychosocial Research. Lymphat Res Biol. 2021 Feb;19(1):36-40. doi: 10.1089/lrb.2020.0095.
- Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus “off-label” therapy for vascular anomalies. Pediatr Blood Cancer. 2021 Feb 13:e28936. doi: 10.1002/pbc.28936.
- Vignes S, Albuisson J, Champion L, Constans J, Tauveron V, Malloizel J, Quéré I, Simon L, Arrault M, Trévidic P, Azria P, Maruani A; French National Referral Center for Primary Primary Lymphoedema French National Diagnosis and Care protocol (PNDS: Protocole National de Diagnostic et de Soins). Orphanet J Rare Dis. 2021 Jan 6;16(1):18. doi: 10.1186/s13023-020-01652-w
- Quéré I, Nagot N, Vikkula M. Incidence of Cellulitis among Children with Primary Lymphedema. N Engl J Med. 2018 :24;378(21):2047-2048.
- Amyere M, Revencu N, …,Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. 2017 Sep 12;136(11):1037-1048.
- Bessis D, Vernhet H, Bigorre M, Quéré I, Rössler J. Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus. JAMA Dermatol. 2016;152(9):1058-9
- Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E,Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M; Lymphedema Research Group. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013;4(6):257-66.
National Diploma of Lymphology, 2003, University of Montpellier: 75 hours e-learning teaching and 5 days of training in hospital.